Patient characteristics of patients with AML with mutated NPM1
| . | No FLT3-ITD (n = 187) . | FLT3-ITD (n = 123) . | Total (n = 310) . | P-value . |
|---|---|---|---|---|
| Age, y | P = .204 | |||
| Median | 52 | 53 | 52 | |
| Range | 19-65 | 26-66 | 19-66 | |
| Sex, n (%) | P = .561 | |||
| M | 91 (49) | 55 (45) | 146 (47) | |
| F | 96 (51) | 68 (55) | 164 (53) | |
| ELN risk classification (%) | P < .001 | |||
| Favorable | 182 (97) | 1 (1) | 183 (59) | |
| Intermediate | 0 (0) | 121 (98) | 121 (39) | |
| Adverse | 5 (3) | 1 (1) | 6 (2) | |
| Disease type (%) | P = .565 | |||
| De novo AML | 186 (99.5) | 121 (98) | 307 (99) | |
| Therapy-related AML | 1 (0.5) | 2 (2) | 3 (1) | |
| WBC at diagnosis, n (%) | P = .013 | |||
| <100 × 109/L | 171 (91) | 100 (81) | 271 (87) | |
| >100 × 109/L | 16 (9) | 23 (19) | 39 (13) | |
| Last treatment before first CR, n (%) | P = .243 | |||
| Cycle 1 | 172 (92) | 108 (88) | 280 (90) | |
| Cycle 2 | 15 (8) | 15 (12) | 30 (10) | |
| Consolidation therapy, n (%) | P < .001 | |||
| None | 16 (9) | 15 (12) | 31 (10) | |
| Chemotherapy | 55 (29) | 17 (14) | 72 (23) | |
| Autologous HSCT | 88 (47) | 23 (19) | 111 (36) | |
| Allogeneic HSCT | 28 (15) | 68 (55) | 96 (31) | |
| Cytogenetics, n (%)∗ | P = .015 | |||
| Normal karyotype | 158 (87) | 113 (96) | 271 (91) | |
| Aberrant karyotype | 23 (13) | 5 (4) | 28 (9) | |
| Mutations at diagnosis, n (%) | P = .035 | |||
| DNMT3A | ||||
| Wild-type | 92 (49) | 45 (37) | 137 (44) | |
| Mutant | 95 (51) | 78 (63) | 173 (56) |
| . | No FLT3-ITD (n = 187) . | FLT3-ITD (n = 123) . | Total (n = 310) . | P-value . |
|---|---|---|---|---|
| Age, y | P = .204 | |||
| Median | 52 | 53 | 52 | |
| Range | 19-65 | 26-66 | 19-66 | |
| Sex, n (%) | P = .561 | |||
| M | 91 (49) | 55 (45) | 146 (47) | |
| F | 96 (51) | 68 (55) | 164 (53) | |
| ELN risk classification (%) | P < .001 | |||
| Favorable | 182 (97) | 1 (1) | 183 (59) | |
| Intermediate | 0 (0) | 121 (98) | 121 (39) | |
| Adverse | 5 (3) | 1 (1) | 6 (2) | |
| Disease type (%) | P = .565 | |||
| De novo AML | 186 (99.5) | 121 (98) | 307 (99) | |
| Therapy-related AML | 1 (0.5) | 2 (2) | 3 (1) | |
| WBC at diagnosis, n (%) | P = .013 | |||
| <100 × 109/L | 171 (91) | 100 (81) | 271 (87) | |
| >100 × 109/L | 16 (9) | 23 (19) | 39 (13) | |
| Last treatment before first CR, n (%) | P = .243 | |||
| Cycle 1 | 172 (92) | 108 (88) | 280 (90) | |
| Cycle 2 | 15 (8) | 15 (12) | 30 (10) | |
| Consolidation therapy, n (%) | P < .001 | |||
| None | 16 (9) | 15 (12) | 31 (10) | |
| Chemotherapy | 55 (29) | 17 (14) | 72 (23) | |
| Autologous HSCT | 88 (47) | 23 (19) | 111 (36) | |
| Allogeneic HSCT | 28 (15) | 68 (55) | 96 (31) | |
| Cytogenetics, n (%)∗ | P = .015 | |||
| Normal karyotype | 158 (87) | 113 (96) | 271 (91) | |
| Aberrant karyotype | 23 (13) | 5 (4) | 28 (9) | |
| Mutations at diagnosis, n (%) | P = .035 | |||
| DNMT3A | ||||
| Wild-type | 92 (49) | 45 (37) | 137 (44) | |
| Mutant | 95 (51) | 78 (63) | 173 (56) |
F, female; HSCT, hematopoietic stem cell transplant; M, male; WBC, white blood cell.
Cytogenetics failed in 11 patients.